Cardiol Therapeutics (CRDL) News Today

Shares of Cardiol Therapeutics Inc. (NASDAQ:CRDL - Get Free Report) have received a consensus recommendation of "Buy" from the seven research firms that are covering the firm, Marketbeat.com reports. Six investment analysts have rated the stock with a buy recommendation and one has issued a stron

Cardiol Therapeutics Inc. (NASDAQ:CRDL - Free Report) - Investment analysts at Roth Capital dropped their Q2 2024 earnings per share estimates for Cardiol Therapeutics in a report released on Tuesday, July 16th. Roth Capital analyst J. Wittes now expects that the company will post earnings of ($0

Cardiol Therapeutics Inc. (NASDAQ:CRDL - Get Free Report) was the recipient of a significant growth in short interest during the month of June. As of June 15th, there was short interest totalling 776,300 shares, a growth of 107.6% from the May 31st total of 374,000 shares. Based on an average trading volume of 501,700 shares, the days-to-cover ratio is presently 1.5 days. Currently, 1.2% of the company's stock are sold short.

Roth Mkm assumed coverage on Cardiol Therapeutics in a research report on Wednesday. They set a "buy" rating and a $10.00 price target on the stock.

Cardiol Therapeutics Inc. (NASDAQ:CRDL - Get Free Report) was the recipient of a large growth in short interest in May. As of May 31st, there was short interest totalling 374,000 shares, a growth of 40.3% from the May 15th total of 266,500 shares. Currently, 0.6% of the shares of the stock are short sold. Based on an average trading volume of 360,800 shares, the short-interest ratio is presently 1.0 days.

HC Wainwright reiterated a "buy" rating and set a $9.00 target price on shares of Cardiol Therapeutics in a research report on Friday.

HC Wainwright reaffirmed a "buy" rating and set a $9.00 target price on shares of Cardiol Therapeutics in a report on Friday.

HC Wainwright restated a "buy" rating and set a $9.00 price target on shares of Cardiol Therapeutics in a research note on Tuesday.

Cardiol Therapeutics Inc. (NASDAQ:CRDL - Free Report) - Stock analysts at HC Wainwright issued their Q1 2024 earnings per share (EPS) estimates for Cardiol Therapeutics in a research report issued to clients and investors on Monday, April 22nd. HC Wainwright analyst V. Bernardino expects that the

HC Wainwright started coverage on Cardiol Therapeutics in a report on Monday. They issued a "buy" rating and a $9.00 price objective on the stock.

Cardiol Therapeutics Inc. (NASDAQ:CRDL - Free Report) - Analysts at Leede Jones Gab boosted their FY2024 EPS estimates for Cardiol Therapeutics in a note issued to investors on Monday, March 25th. Leede Jones Gab analyst D. Loe now anticipates that the company will earn ($0.31) per share for the

Cardiol Therapeutics (NASDAQ:CRDL) will be releasing earnings on Tuesday, March 26, Yahoo Finance reports.

Cardiol Therapeutics Inc. (NASDAQ:CRDL - Get Free Report) was the recipient of a significant increase in short interest during the month of February. As of February 29th, there was short interest totalling 361,100 shares, an increase of 108.1% from the February 14th total of 173,500 shares. Approximately 0.6% of the company's stock are sold short. Based on an average daily volume of 335,900 shares, the short-interest ratio is currently 1.1 days.

Cardiol Therapeutics Inc. (NASDAQ:CRDL - Get Free Report) was the recipient of a significant decrease in short interest in January. As of January 15th, there was short interest totalling 119,600 shares, a decrease of 9.0% from the December 31st total of 131,500 shares. Approximately 0.2% of the shares of the company are sold short. Based on an average trading volume of 144,800 shares, the days-to-cover ratio is presently 0.8 days.